Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities.
ACS Infect Dis.
2024 May 10;10(5):1679-1695. doi: 10.1021/acsinfecdis.4c00025. Epub 2024 Apr 6. PubMed PMID:
38581700.
Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
Antimicrob Agents Chemother.
2024 May 2;68(5):e0101023. doi: 10.1128/aac.01010-23. Epub 2024 Mar 19. PubMed PMID:
38501805; PubMed Central PMCID:
PMC11064538.
Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice.
mBio.
2023 Dec 19;14(6):e0236323. doi: 10.1128/mbio.02363-23. Epub 2023 Oct 31. PubMed PMID:
37905920; PubMed Central PMCID:
PMC10746229.
Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses.
Antimicrob Agents Chemother.
2023 Sep 19;67(9):e0028423. doi: 10.1128/aac.00284-23. Epub 2023 Aug 11. PubMed PMID:
37565762; PubMed Central PMCID:
PMC10508168.
Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics.
Pharmaceutics.
2023 Jun 17;15(6). doi: 10.3390/pharmaceutics15061759. PubMed PMID:
37376207; PubMed Central PMCID:
PMC10305115.
Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.
Tuberculosis (Edinb).
2023 May;140:102342. doi: 10.1016/j.tube.2023.102342. Epub 2023 Apr 20. PubMed PMID:
37120915; PubMed Central PMCID:
PMC10247484.
Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency.
Antimicrob Agents Chemother.
2023 Jan 24;67(1):e0148322. doi: 10.1128/aac.01483-22. Epub 2023 Jan 9. PubMed PMID:
36622159; PubMed Central PMCID:
PMC9872615.
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
Antimicrob Agents Chemother.
2022 Jun 21;66(6):e0013222. doi: 10.1128/aac.00132-22. Epub 2022 May 24. PubMed PMID:
35607978; PubMed Central PMCID:
PMC9211396.
Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
Antimicrob Agents Chemother.
2022 Apr 19;66(4):e0231021. doi: 10.1128/aac.02310-21. Epub 2022 Mar 21. PubMed PMID:
35311519; PubMed Central PMCID:
PMC9017352.
Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
Antimicrob Agents Chemother.
2022 Apr 19;66(4):e0219221. doi: 10.1128/aac.02192-21. Epub 2022 Mar 10. PubMed PMID:
35266826; PubMed Central PMCID:
PMC9017349.
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
J Med Chem.
2022 Mar 24;65(6):4481-4495. doi: 10.1021/acs.jmedchem.1c02045. Epub 2022 Feb 17. PubMed PMID:
35175750; PubMed Central PMCID:
PMC8958509.
Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.
J Med Chem.
2022 Jan 13;65(1):409-423. doi: 10.1021/acs.jmedchem.1c01586. Epub 2021 Dec 15. PubMed PMID:
34910486; PubMed Central PMCID:
PMC8762665.
New Investigations with Lupane Type A-Ring Azepane Triterpenoids for Antimycobacterial Drug Candidate Design.
Int J Mol Sci.
2021 Nov 21;22(22). doi: 10.3390/ijms222212542. PubMed PMID:
34830423; PubMed Central PMCID:
PMC8621456.
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832.
Antimicrob Agents Chemother.
2021 Oct 18;65(11):e0058321. doi: 10.1128/AAC.00583-21. Epub 2021 Aug 9. PubMed PMID:
34370580; PubMed Central PMCID:
PMC8522729.
Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.
Antimicrob Agents Chemother.
2021 Oct 18;65(11):e0174420. doi: 10.1128/AAC.01744-20. Epub 2021 Aug 23. PubMed PMID:
34424046; PubMed Central PMCID:
PMC8522768.
Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis.
ACS Infect Dis.
2021 Oct 8;7(10):2850-2863. doi: 10.1021/acsinfecdis.1c00213. Epub 2021 Sep 21. PubMed PMID:
34546724; PubMed Central PMCID:
PMC10226119.
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis.
J Med Chem.
2021 Sep 9;64(17):12790-12807. doi: 10.1021/acs.jmedchem.1c00837. Epub 2021 Aug 20. PubMed PMID:
34414766; PubMed Central PMCID:
PMC10500703.
The Tuberculosis Drug Accelerator at year 10: what have we learned?.
Nat Med.
2021 Aug;27(8):1333-1337. doi: 10.1038/s41591-021-01442-2. PubMed PMID:
34226736; PubMed Central PMCID:
PMC10478072.
Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.
Nat Commun.
2021 May 18;12(1):2899. doi: 10.1038/s41467-021-22833-6. PubMed PMID:
34006838; PubMed Central PMCID:
PMC8131613.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.
ACS Omega.
2021 Jan 26;6(3):2284-2311. doi: 10.1021/acsomega.0c05589. eCollection 2021 Jan 26. PubMed PMID:
33521468; PubMed Central PMCID:
PMC7841955.
Synthesis, Structure-Activity Relationship, and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial Activity.
ACS Infect Dis.
2020 Jul 10;6(7):1951-1964. doi: 10.1021/acsinfecdis.0c00252. Epub 2020 Jun 15. PubMed PMID:
32470286; PubMed Central PMCID:
PMC7359024.
Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks.
Sci Rep.
2020 Apr 8;10(1):6047. doi: 10.1038/s41598-020-62960-6. PubMed PMID:
32269234; PubMed Central PMCID:
PMC7142129.
Allosteric inhibitors of Mycobacterium tuberculosis tryptophan synthase.
Protein Sci.
2020 Mar;29(3):779-788. doi: 10.1002/pro.3825. Epub 2020 Jan 20. PubMed PMID:
31930594; PubMed Central PMCID:
PMC7020977.
Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.
Antimicrob Agents Chemother.
2019 Apr;63(4). doi: 10.1128/AAC.02071-18. Print 2019 Apr. PubMed PMID:
30745397; PubMed Central PMCID:
PMC6496157.
Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.
Life Sci Alliance.
2018 Jun;1(3):e201800025. doi: 10.26508/lsa.201800025. eCollection 2018 Jun. PubMed PMID:
30456352; PubMed Central PMCID:
PMC6238539.
Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.
Cell.
2017 Jul 13;170(2):249-259.e25. doi: 10.1016/j.cell.2017.06.025. Epub 2017 Jun 29. PubMed PMID:
28669536; PubMed Central PMCID:
PMC5509550.
Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
J Antimicrob Chemother.
2017 Mar 1;72(3):770-777. doi: 10.1093/jac/dkw467. PubMed PMID:
27999020; PubMed Central PMCID:
PMC5400088.
Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions.
ACS Infect Dis.
2017 Jan 13;3(1):72-88. doi: 10.1021/acsinfecdis.6b00158. Epub 2016 Nov 11. PubMed PMID:
28081607; PubMed Central PMCID:
PMC5493200.
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
J Med Chem.
2014 Nov 13;57(21):8947-59. doi: 10.1021/jm501082n. Epub 2014 Oct 15. PubMed PMID:
25280369.
FTT0831c/FTL_0325 contributes to Francisella tularensis cell division, maintenance of cell shape, and structural integrity.
Infect Immun.
2014 Jul;82(7):2935-48. doi: 10.1128/IAI.00102-14. Epub 2014 Apr 28. PubMed PMID:
24778115; PubMed Central PMCID:
PMC4097634.
IglE is an outer membrane-associated lipoprotein essential for intracellular survival and murine virulence of type A Francisella tularensis.
Infect Immun.
2013 Nov;81(11):4026-40. doi: 10.1128/IAI.00595-13. Epub 2013 Aug 19. PubMed PMID:
23959721; PubMed Central PMCID:
PMC3811846.
Method for the isolation of Francisella tularensis outer membranes.
J Vis Exp.
2010 Jun 29;(40). doi: 10.3791/2044. PubMed PMID:
20613713; PubMed Central PMCID:
PMC3156061.
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Antimicrob Agents Chemother.
2008 Jul;52(7):2313-23. doi: 10.1128/AAC.01649-07. Epub 2008 Apr 28. PubMed PMID:
18443108; PubMed Central PMCID:
PMC2443886.
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.
Antimicrob Agents Chemother.
2008 Jul;52(7):2324-34. doi: 10.1128/AAC.01651-07. Epub 2008 Apr 28. PubMed PMID:
18443106; PubMed Central PMCID:
PMC2443883.
Bacterial and fungal biofilm infections.
Annu Rev Med.
2008;59:415-28. doi: 10.1146/annurev.med.59.110106.132000. Review. PubMed PMID:
17937586.
A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM.
J Bacteriol.
2007 Oct;189(19):6870-81. doi: 10.1128/JB.00805-07. Epub 2007 Jul 20. PubMed PMID:
17644596; PubMed Central PMCID:
PMC2045200.
New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.
Bioorg Med Chem Lett.
2007 Jan 15;17(2):522-6. doi: 10.1016/j.bmcl.2006.10.016. Epub 2006 Oct 12. PubMed PMID:
17070048.
Use of an efflux-deficient streptococcus pneumoniae strain panel to identify ABC-class multidrug transporters involved in intrinsic resistance to antimicrobial agents.
Antimicrob Agents Chemother.
2005 Nov;49(11):4781-3. doi: 10.1128/AAC.49.11.4781-4783.2005. PubMed PMID:
16251330; PubMed Central PMCID:
PMC1280156.
Role of HdeA in acid resistance and virulence in Brucella abortus 2308.
Vet Microbiol.
2005 May 20;107(3-4):307-12. doi: 10.1016/j.vetmic.2005.01.018. PubMed PMID:
15863292.
The Brucella abortus Cu,Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice.
Infect Immun.
2005 May;73(5):2873-80. doi: 10.1128/IAI.73.5.2873-2880.2005. PubMed PMID:
15845493; PubMed Central PMCID:
PMC1087332.
Constitutive expression of PcsB suppresses the requirement for the essential VicR (YycF) response regulator in Streptococcus pneumoniae R6.
Mol Microbiol.
2003 Dec;50(5):1647-63. doi: 10.1046/j.1365-2958.2003.03806.x. PubMed PMID:
14651645.
Brucella stationary-phase gene expression and virulence.
Annu Rev Microbiol.
2003;57:57-76. doi: 10.1146/annurev.micro.57.030502.090803. Epub 2003 May 1. Review. PubMed PMID:
12730323.
Essentiality of clpX, but not clpP, clpL, clpC, or clpE, in Streptococcus pneumoniae R6.
J Bacteriol.
2003 May;185(9):2961-6. doi: 10.1128/JB.185.9.2961-2966.2003. PubMed PMID:
12700276; PubMed Central PMCID:
PMC154392.
Interactions between Brucella melitensis and human phagocytes: bacterial surface O-Polysaccharide inhibits phagocytosis, bacterial killing, and subsequent host cell apoptosis.
Infect Immun.
2003 Apr;71(4):2110-9. doi: 10.1128/IAI.71.4.2110-2119.2003. PubMed PMID:
12654833; PubMed Central PMCID:
PMC152029.
Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors.
J Bacteriol.
2003 Jan;185(1):359-70. doi: 10.1128/JB.185.1.359-370.2003. PubMed PMID:
12486074; PubMed Central PMCID:
PMC141824.
Seeking a niche: putative contributions of the hfq and bacA gene products to the successful adaptation of the brucellae to their intracellular home.
Vet Microbiol.
2002 Dec 20;90(1-4):349-63. doi: 10.1016/s0378-1135(02)00220-1. Review. PubMed PMID:
12414155.
Vancomycin tolerance induced by erythromycin but not by loss of vncRS, vex3, or pep27 function in Streptococcus pneumoniae.
J Bacteriol.
2002 Dec;184(24):6987-7000. doi: 10.1128/JB.184.24.6987-7000.2002. PubMed PMID:
12446649; PubMed Central PMCID:
PMC135460.
Major histocompatibility complex class I and II expression on macrophages containing a virulent strain of Brucella abortus measured using green fluorescent protein-expressing brucellae and flow cytometry.
FEMS Immunol Med Microbiol.
2002 Jul 12;33(3):191-200. doi: 10.1111/j.1574-695X.2002.tb00590.x. PubMed PMID:
12110481.
Global transcriptional analysis of clpP mutations of type 2 Streptococcus pneumoniae and their effects on physiology and virulence.
J Bacteriol.
2002 Jul;184(13):3508-20. doi: 10.1128/JB.184.13.3508-3520.2002. PubMed PMID:
12057945; PubMed Central PMCID:
PMC135132.
Streptococcus pneumoniae as a genomics platform for broad-spectrum antibiotic discovery.
Curr Opin Microbiol.
2002 Jun;5(3):338-42. doi: 10.1016/s0959-4388(02)90328-4. Review. PubMed PMID:
12057692.
What would you like to do?